Press coverage about Intec Pharma (NASDAQ:NTEC) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intec Pharma earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.3544678740183 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several equities analysts recently weighed in on NTEC shares. Oppenheimer Holdings, Inc. set a $15.00 target price on Intec Pharma and gave the stock a “buy” rating in a research report on Friday, October 13th. Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. CIBC reiterated an “outperform” rating and set a $15.00 target price (up from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Finally, Roth Capital set a $10.00 target price on Intec Pharma and gave the stock a “buy” rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Intec Pharma has an average rating of “Buy” and a consensus target price of $12.25.
Shares of Intec Pharma (NASDAQ:NTEC) remained flat at $8.20 during midday trading on Friday. The stock had a trading volume of 17,566 shares. The firm has a 50 day moving average price of $8.51 and a 200-day moving average price of $8.51. Intec Pharma has a 52-week low of $4.20 and a 52-week high of $9.80. The company’s market cap is $112.65 million.
TRADEMARK VIOLATION NOTICE: “Intec Pharma (NTEC) Given Media Sentiment Rating of 0.17” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/intec-pharma-ntec-receiving-somewhat-favorable-press-coverage-analysis-shows.html.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.